Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
COMPASS is a status and intervention study for the self-monitoring of blood glucose (SMBG) in type 2 diabetic patients with insulin treatment. This multi-centre, open-label prospective study will assess the use and frequency of SMBG and blood glucose control and its influencing factors with the help of Accu-Chek Integra glucometer. Patients with type 2 diabetes mellitus who have received more than 3 months of insulin therapy are eligible to participate in this study. The anticipated duration of the study is 6 months.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| A | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Accu-Chek Integra Glucometer | Device |
|
| Measure | Description | Time Frame |
|---|---|---|
| HbA1c change between the baseline and end of study | From baseline to month 6 | |
| Successful rate of blood glucose control (the proportion of patients with HbA1c <7%) | From baseline to month 6 |
| Measure | Description | Time Frame |
|---|---|---|
| SMBG frequency change between the baseline and the end of the study | From baseline to month 6 | |
| Relationship between SMBG frequency change and blood glucose control | From baseline to month 6 | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bettina Petersen | Roche Diagnostics (Shanghai) Ltd | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Beijing | 100020 | China | ||||
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| To evaluate the change of quality of life in the 6 months by the health questionnaire SF-36 |
| From baseline to month 6 |
| Beijing |
| 100034 |
| China |
| Beijing | 100044 | China |
| Beijing | 100730 | China |
| Chengdu | 610041 | China |
| Guangzhou | 510080 | China |
| Guangzhou | 510120 | China |
| Guangzhou | 510515 | China |
| Hangzhou | 310003 | China |
| Nanjing | 210008 | China |
| Nanjing | 210029 | China |
| Shanghai | 2000092 | China |
| Shanghai | 200040 | China |
| Shanghai | 200120 | China |
| Shanghai | 200433 | China |
| Shenyang | 110001 | China |
| Tianjin | 300070 | China |
| Wuhan | 430030 | China |
| Xi'an | 710061 | China |
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided